Race may influence prostate cancer drug response, study investigates
NCT ID NCT03833921
Summary
This study follows men with advanced prostate cancer who are receiving standard treatment with abiraterone and prednisone. Researchers want to understand if a patient's race or ethnicity affects how well these medications work to control the cancer. The study will track 130 participants for up to 10 years, measuring their PSA levels and disease progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ben Taub General Hospital
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Michael E. DeBakey Veterans Affairs Medical Center
ACTIVE_NOT_RECRUITINGHouston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.